Nexlizet: Uses, Dosage, Side Effects, Warnings - Drugs.com
Sep 26, 2024 · Nexlizet may cause the following serious side effects. Increased levels of uric acid in your blood (hyperuricemia). This can happen within 4 weeks of starting Nexlizet and can …
Nonstatin Cholesterol Medications - NEXLIZET® & NEXLETOL®
NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe. The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart …
Nexlizet (Bempedoic acid and Ezetimibe) for Heart Disease
Nexlizet is indicated as an adjunct therapy to diet and maximally-tolerated statin therapy. Nexlizet is a combination treatment of two drugs, bempedoic acid and ezetimibe. Bempedoic acid is a …
INDICATION NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established …
Nexlizet (bempedoic acid/ezetimibe) - Uses, Side ... - WebMD
Jun 30, 2024 · What is Nexlizet used for? Nexlizet (bempedoic acid/ ezetimibe) is commonly used for the following conditions. To lower the risk of heart attack and certain heart procedures like …
Esperion’s Bempedoic Acid Receives Recommendation in 2025
3 days ago · The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, …
NEXLIZET® & NEXLETOL® HCP Information - Official Site
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than …
Bempedoic acid, a component of NEXLIZET, is used: to lower the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, …
Nexlizet: Dosage, side effects, uses, interactions, cost, and ...
Apr 4, 2025 · Dosage for reducing certain cardiovascular risks Nexlizet is approved to help reduce the risk of heart attack and coronary revascularization (a type of heart procedure) in certain …
Adverse reactions led to discontinuation of treatment in 8% of patients on NEXLIZET, 5% of patients on placebo, 10% of patients on bempedoic acid, and 12% of patients on ezetimibe.